Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 9/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4979111 | 0.66 | OPRD1 (0.37) | OPRD1OPRK1OPRM1 | |
| SCHEMBL14284041 | 0.61 | DRD2 (0.44) | OPRD1OPRK1OPRM1 | |
| SCHEMBL29786181 | 0.56 | TRPA1 (0.37) | OPRD1OPRK1OPRM1 | |
| SCHEMBL4980281 | 0.56 | CCR2 (0.33) | — | |
| SCHEMBL4980288 | 0.56 | CCR2 (0.33) | — | |
| SCHEMBL9358209 | 0.55 | LMNA (0.38) | MAPT | |
| SCHEMBL9362699 | 0.55 | ALDH1A1 (0.44) | MAPTTMEM97SIGMAR1 | |
| SCHEMBL11729674 | 0.54 | CA1 (0.41) | — | |
| SCHEMBL6943167 | 0.54 | GBA1 (0.42) | GRIN2B | |
| SCHEMBL1044189 | 0.54 | KMT2A (0.54) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080021038-A1 | Novel Piperidine/8-Azabicyclo [3.2.1.] Octan Derivatives As Modulators Of Chemokine Receptor Ccr5 | TUCKER HOWARD | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021038-A1 | Novel Piperidine/8-Azabicyclo [3.2.1.] Octan Derivatives As Modulators Of Chemokine Receptor Ccr5 | CCR5, CXCR1, CCR2 | OPRD1 30/4885OPRK1 51/4885MAPT 4553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.